ALLIANCE TRIAL AT-A-GLANCE

Title
A Phase 2 Randomized Study of Efatutazone, an Oral PPAR Agonist, in Combination with Paclitaxel Versus Paclitaxel in Patients with Advanced Anaplastic Thyroid Cancer

Study Chair
Robert C. Smallridge, MD
Deputy Director, Mayo Clinical Cancer Center
Alfred D. and Audrey M. Petersen Professor in Cancer Research
Mayo Clinic Florida

E-mail: smallridge.robert@mayo.edu

Details
- Status: **Accepting New Patients**
- Study Type: Therapeutic, Treatment
- Protocol No: Alliance A091305
- ClinicalTrial.gov Identifier: NCT02152137

Purpose
The purpose of this study is to determine how well efatutazone with paclitaxel compared to paclitaxel alone works in treating patients with advanced anaplastic thyroid cancer.

Overview
Drugs used in chemotherapy, such as efatutazone and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells by stopping them from dividing or by stopping them from spreading. It is not yet known whether efatutazone in combination with paclitaxel is more effective than paclitaxel alone in treating patients with advanced anaplastic thyroid cancer.

This is a phase II randomized study for patients with advanced anaplastic thyroid cancer. Patients will be randomized to one of two treatment arms, efatutazone in combination with paclitaxel or paclitaxel alone. Treatment will consist of continuous cycles administered every 21 days. Treatment will continue until disease progression, unacceptable adverse events, or a minimum of two cycles beyond a complete response.

Eligibility
Some eligibility criteria for the study includes:
- The diagnosis of advanced anaplastic thyroid cancer (ATC)
- The disease is either metastatic (stage IVC) or locally advanced unresectable disease (stage IVB)
- No prior taxane therapy more than 6 months, except as a radiosensitizer.

Note: This is only a partial list of eligibility criteria. Please contact the study chair for complete screening information if you are interested in this clinical trial.

About the Alliance
To learn more about the Alliance for Clinical Trials in Oncology, visit our website.